Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Aria Health-Torresdale Campus
mi
from
Philadelphia, PA
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Aria Health-Torresdale Campus
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Avera Cancer Institute
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Avera McKennan Hospital and University Health Center
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Gundersen Lutheran Medical Center
mi
from
La Crosse, WI
Click here to add this to my saved trials
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer
Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Clearview Cancer Institute
mi
from
Huntsville, AL
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Clearview Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mobile Infirmary Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Hospital,
mi
from
Mobile, AL
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Hospital,
mi
from
Mobile, AL
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Banner Good Samaritan Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Western Regional CCOP
mi
from
Phoenix, AZ
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Western Regional CCOP
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Arizona Medical Center University Campus
mi
from
Tucson, AZ
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Arizona Medical Center University Campus
mi
from
Tucson, AZ
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Sparks Regional Medical Center
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mercy Cancer Center-Hot Springs
mi
from
Hot Springs, AR
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mercy Cancer Center-Hot Springs
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group-Rogers
mi
from
Rogers, AR
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group-Rogers
mi
from
Rogers, AR
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Saint Joseph Medical Center-Disney Family Cancer Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Mills - Peninsula Hospitals
mi
from
Burlingame, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Mills - Peninsula Hospitals
mi
from
Burlingame, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Eden Hospital Medical Center
mi
from
Castro Valley, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Eden Hospital Medical Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology Consultants - Castro Valley
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
John Muir Medical Center - Concord Campus
mi
from
Concord, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
John Muir Medical Center - Concord Campus
mi
from
Concord, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Bay Area Breast Surgeons Inc
mi
from
Emeryville, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Bay Area Breast Surgeons Inc
mi
from
Emeryville, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Northbay Cancer Center
mi
from
Fairfield, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Northbay Cancer Center
mi
from
Fairfield, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente - Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Valley Medical Oncology Consultants-Fremont
mi
from
Fremont, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Valley Medical Oncology Consultants-Fremont
mi
from
Fremont, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Washington Hospital
mi
from
Fremont, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Washington Hospital
mi
from
Fremont, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Saint Jude Medical Center
mi
from
Fullerton, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Saint Jude Medical Center
mi
from
Fullerton, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Glendale Memorial Hospital and Health Center
mi
from
Glendale, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Glendale Memorial Hospital and Health Center
mi
from
Glendale, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Marin Cancer Care, Inc.
mi
from
Greenbrae, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Marin Cancer Care, Inc.
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Marin General Hospital
mi
from
Greenbrae, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Marin General Hospital
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Saint Rose Hospital
mi
from
Hayward, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Saint Rose Hospital
mi
from
Hayward, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Contra Costa Regional Medical Center
mi
from
Martinez, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Fremont - Rideout Cancer Center
mi
from
Marysville, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Fremont - Rideout Cancer Center
mi
from
Marysville, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Community Hospital of the Monterey Peninsula
mi
from
Monterey, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Community Hospital of the Monterey Peninsula
mi
from
Monterey, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
El Camino Hospital
mi
from
Mountain View, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
El Camino Hospital
mi
from
Mountain View, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation-Camino Division
mi
from
Mountain View, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation-Camino Division
mi
from
Mountain View, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Northridge Hospital Medical Center
mi
from
Northridge, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Northridge Hospital Medical Center
mi
from
Northridge, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Research Consortium
mi
from
Novato, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Research Consortium
mi
from
Novato, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Highland General Hospital
mi
from
Oakland, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Highland General Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery
ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center - Summit Campus
mi
from
Oakland, CA
Click here to add this to my saved trials